Biggest News Aggregation in the World
๐Ÿ“ฐ Allo News

Page 10 - Allo News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Allo. Real-time updates on events, politics, business and more.

Allogene Therapeutics (NASDAQ:ALLO) PT Lowered to $7.50

Allogene Therapeutics (NASDAQ:ALLO – Get Rating) had its price target reduced by Stifel Nicolaus from $8.00 to $7.50 in a research note released on Thursday, The Fly reports. Several other research analysts also recently commented on ALLO. Robert W. Baird raised shares of Allogene Therapeutics from a neutral rating to an outperform rating and set […]
Robertw Baird Stifel Nicolaus Penserra Capital Management Allogene Therapeutics Inc Nordwand Advisors Allspring Global Investments Holdings

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives $17.58 Average Price Target from Analysts

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Rating) has been given a consensus recommendation of “Moderate Buy” by the fifteen ratings firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and eight have assigned a buy recommendation to the company. The […]
Robertw Baird William Blair Allogene Therapeutics Inc Ci Investments Inc Penserra Capital Management Allspring Global Investments Holdings

Allogene Therapeutics (NASDAQ:ALLO) Posts Earnings Results, Misses Estimates By $0.05 EPS

Allogene Therapeutics (NASDAQ:ALLO – Get Rating) issued its earnings results on Wednesday. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.05), Briefing.com reports. The business had revenue of $0.05 million during the quarter, compared to analyst estimates of $0.08 million. Allogene Therapeutics had a negative net […]
Stifel Nicolaus Sanfordc Bernstein Allogene Therapeutics Company Profile Millennium Management Allogene Therapeutics Inc Goldman Sachs Group Inc

Allogene Therapeutics (NASDAQ:ALLO) Given New $7.50 Price Target at Stifel Nicolaus

Allogene Therapeutics (NASDAQ:ALLO – Get Rating) had its price target lowered by investment analysts at Stifel Nicolaus from $8.00 to $7.50 in a research report issued on Thursday, The Fly reports. Stifel Nicolaus’ target price suggests a potential upside of 31.12% from the company’s current price. Other equities research analysts have also issued research reports […]
Stifel Nicolau Stifel Nicolaus Proshare Advisors Ensign Peak Advisors Inc Metlife Investment Management Allogene Therapeutics Inc
Source: wkrb13.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News โ†’

MSNBC Symone June 4, 2024 20:53:00

Real ones from the fake. ive had friends, i have a few celebrity friends. and they have had people impersonating them, asking for money through the internet that alone, it creates a problem once you start to make people pay for it, or allo anybody to have the blue check its definitely a problem. >> shelby, you posted on twitter today that you los your belichick and you are not -- your belichick is gone is gone for good are you going to pay 80 bucks? >> no. i sit out the gate, im no paying eight ...
Celebrity Friends Ayou Los Rules Abou Twitter It Doesn T Matter 180 Bucks

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science